Results 291 to 300 of about 234,444 (394)

Mono and combination therapies in pulmonary arterial hypertension patients with comorbidities: A COMPERA analysis

ESC Heart Failure, EarlyView.
AIM This analysis provides a comparison of the efficacy of initial mono and combination therapy in patients with PAH and cardiovascular comorbidities or with risk factors of HFpEF (heart failure with preserved ejection fractioin).METHOD Data from the European COMPERA registry were used for a matched pair analysis.
Dirk Skowasch, Christine Pausch, Doerte Huscher, David Pittrow, Judith Wede, Fabian Kreimendahl, Stephan Rosenkranz, Stephan Beckmann, Matthias Held, Ekkehard Grünig, H. Ardeschir Ghofrani, Hans Klose, Andris Skride, Michael Halank, Stefan Stadler, Marion Delcroix, Anton Vonk‐Noordegraaf, Ralf Ewert, Grzegorz Kopec, Marius M. Hoeper, Karen M. Olsson   +20 more
wiley   +1 more source

Beneficial Impact of Nutritional Therapy on Idiopathic Pulmonary Fibrosis. [PDF]

Cureus
Yamakawa H, Ohta H, Sato S, Matsushima H.   +3 more
europepmc   +1 more source

Association of tracheal diameter with respiratory function and fibrosis severity in idiopathic pulmonary fibrosis patients. [PDF]

BMC Pulm Med
Fazlıoğlu N, Sasani H, Fazlıoğlu M, Çiftçi EP, Mutlu LC.   +4 more
europepmc   +1 more source

Finerenone, chronic obstructive pulmonary disease, and heart failure with mildly reduced or preserved ejection fraction: A prespecified analysis of the FINEARTS‐HF trial

European Journal of Heart Failure, EarlyView.
The beneficial effects of finerenone in patients with heart failure (HF) and mildly reduced or preserved ejection fraction were consistent, regardless of a history of chronic obstructive pulmonary disease (COPD) status. BMI, body mass index; LVEF, left ventricular ejection fraction; NT‐proBNP, N‐terminal pro‐B‐type natriuretic peptide.
Jawad H. Butt, Pardeep S. Jhund, Alasdair D. Henderson, Brian L. Claggett, Akshay S. Desai, Carolyn S.P. Lam, Katharina Mueller, Markus F. Scheerer, Prabhakar Viswanathan, Michele Senni, Sanjiv J. Shah, Adriaan A. Voors, Faiez Zannad, Bertram Pitt, Muthiah Vaduganathan, Scott D. Solomon, John J.V. McMurray   +16 more
wiley   +1 more source

Role of genetic modifiers on pulmonary consequences of cancer therapy in children. [PDF]

Sci Rep
Dobkin SL, Chang X, Mentch F, Hakonarson H.   +3 more
europepmc   +1 more source

The significance of periostin in the diagnosis of idiopathic pulmonary fibrosis and prediction of acute exacerbations. [PDF]

J Thorac Dis
Wu S, Liu H, Yin S, Wang Y, Liu X, Ding Z.   +5 more
europepmc   +1 more source

The Predictive Role of C-Reactive Protein, Leukocyte Cell Count, and Soluble Urokinase Plasminogen Activator Receptor for Pulmonary Sequelae in Hospitalized COVID-19 Survivors: A Prospective Single-Center Cohort Study. [PDF]

J Clin Med
Altintas I, Kallemose T, Lindstrøm MB, Parvaiz I, Rokkedal I, Rasmussen LJ, Iversen KK, Eugen-Olsen J, Iversen KK, Hansen EF, Ulrik CS, Nehlin JO, Andersen O.   +12 more
europepmc   +1 more source

Interpretation of in vitro concentration‐response data for risk assessment and regulatory decision‐making: Report from the 2022 IWGT quantitative analysis expert working group meeting

Environmental and Molecular Mutagenesis, EarlyView.
Abstract Quantitative risk assessments of chemicals are routinely performed using in vivo data from rodents; however, there is growing recognition that non‐animal approaches can be human‐relevant alternatives. There is an urgent need to build confidence in non‐animal alternatives given the international support to reduce the use of animals in toxicity ...
Marc A. Beal, Guangchao Chen, Kerry L. Dearfield, Min Gi, Bhaskar Gollapudi, Robert H. Heflich, Katsuyoshi Horibata, Alexandra S. Long, David P. Lovell, Barbara L. Parsons, Stefan Pfuhler, John Wills, Andreas Zeller, George Johnson, Paul A. White   +14 more
wiley   +1 more source

Reply to Holbert and Fraidenburg: Not to Be Forgotten. Pulmonary Vascular Effects of Nonmyeloablative Hematopoietic Cell Transplant for Sickle Cell Disease. [PDF]

Ann Am Thorac Soc
Ruhl AP, Limerick EM, Barochia AV, Fitzhugh CD, Hsieh MM.   +4 more
europepmc   +1 more source

Synthetic Biology‐Based Engineering Living Therapeutics for Antimicrobial Application

Exploration, EarlyView.
This perspective highlights synthetic biology‐driven antibacterial strategies, focusing on three innovative approaches: engineered bacteriophages for precision bacterial targeting, reprogrammed microbes that detect quorum‐sensing signals or metabolites to release antimicrobials, and engineering mammalian cells that recognize pathogen‐associated ...
Shun Huang, Shuihao Zhao, Haijie Zhao, Mingzhang Wen, Zhong Guo   +4 more
wiley   +1 more source